Amgen, Inc. (AMGN)’s Drug Trial Fails To Live Up To Expectation

Shares of Amgen, Inc. (NASDAQ:AMGN), which are up almost 16% this year, were trending high in the early afternoon hours, gaining nearly 4% after a day that saw them topple following negative study results. It appears as though investors are now less concerned about the failed trail because the company said the positive results obtained earlier this month would be sufficient to support submissions for regulatory approvals around the world. On CNBC, Yaron Werber, senior biotech analysts at Citi Investment Research, weighed in on the failed study and what lies ahead for the company.

Amgen, Inc. (NASDAQ:AMGN)

Amgen, Inc. (NASDAQ:AMGN) reported that a study of its drug Kyprolis, for a type of blood cancer, failed to help patients live longer compared to the standard care. The study focused on patients with an advanced case of the blood cancer condition known as multiple myeloma. The drug is approved in the U.S., but the company needed survival evidence to obtain approval in Europe.

Coming on to the case of Amgen, Inc. (NASDAQ:AMGN) and the failure of Kyprolis to improve survival rates, Werber said all is not lost for the company because it already has study results that are good enough for approval.

“This is one of the main reasons why Amgen quite earned it. To put it into perspective, they’ve had another study that was successful recently for the drug that will get approved. But overall, if you look at the profile of this drug Kyrolis  myeloma, which is a blood cancer, the overall profile is probably not quite with originally expected, and we think maybe numbers are going to come down,” he said.

He also talked about Amgen, Inc. (NASDAQ:AMGN)’s journey into developing treatment for myeloma and the marketing opportunity for Kyrolis. He noted that the market is there, but the challenge is that patients keep advancing to better drugs that can keep them alive.

“The market is sizable and continues to grow, and as you know, unfortunately, patients with cancer die, and they always progress from one drug to the next [...],” said Werber.

Disclosure: none

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!